KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other financing activities (2016 - 2026)

Teva Pharmaceutical Industries filings provide 16 years of Other financing activities readings, the most recent being $36.0 million for Q1 2026.

  • On a quarterly basis, Other financing activities rose 1100.0% to $36.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $75.0 million, a 1775.0% increase, with the full-year FY2025 number at $41.0 million, up 612.5% from a year prior.
  • Other financing activities hit $36.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $40.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $40.0 million in Q4 2025 to a low of -$76.0 million in Q3 2023.
  • Median Other financing activities over the past 5 years was -$4.0 million (2022), compared with a mean of -$16.2 million.
  • Biggest five-year swings in Other financing activities: plummeted 4100.0% in 2022 and later surged 1100.0% in 2026.
  • Teva Pharmaceutical Industries' Other financing activities stood at -$3.0 million in 2022, then tumbled by 2433.33% to -$76.0 million in 2023, then skyrocketed by 114.47% to $11.0 million in 2024, then surged by 263.64% to $40.0 million in 2025, then dropped by 10.0% to $36.0 million in 2026.
  • The last three reported values for Other financing activities were $36.0 million (Q1 2026), $40.0 million (Q4 2025), and -$2.0 million (Q3 2025) per Business Quant data.